enzon pharmaceuticals, inc., together with its subsidiaries, engages in licensing drug products. its marketed drug products include pegintron and sylatron. the company was founded in 1981 and is headquartered in cranford, new jersey.
Company profile
Ticker
ENZN
Exchange
Website
CEO
Andrew Rackear
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Acorda Therapeutics ...
Former names
ENZON INC, ENZON PHARMACEUTICAL INC, ENZON PHARMACEUTICALS INC, ENZON PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Ventures, Inc. ...
IRS number
222372868
ENZN stock data
Latest filings (excl ownership)
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 23
10-Q
2023 Q1
Quarterly report
5 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
DEFA14A
Additional proxy soliciting materials
20 Apr 23
DEF 14A
Definitive proxy
20 Apr 23
10-K
2022 FY
Annual report
16 Feb 23
8-K
Other Events
6 Jan 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
Latest ownership filings
4
RANDOLPH C READ
16 Jun 23
3
Jaffrey Adam Firestone
21 Jun 22
4
JONATHAN COUCHMAN
17 Aug 21
4
RANDOLPH C READ
18 Nov 20
4
Jordan Bleznick
17 Nov 20
4
CARL C ICAHN
14 Oct 20
SC 13D/A
ICAHN CARL C
14 Oct 20
SC 13D/A
COUCHMAN JONATHAN
17 Sep 20
SC 13D/A
ICAHN CARL C
1 Sep 20
4
JONATHAN COUCHMAN
26 Aug 20
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 46.56 mm | 46.56 mm | 46.56 mm | 46.56 mm | 46.56 mm | 46.56 mm |
| Cash burn (monthly) | (no burn) | 24.58 k | (no burn) | 34.75 k | (no burn) | (no burn) |
| Cash used (since last report) | n/a | 53.11 k | n/a | 75.08 k | n/a | n/a |
| Cash remaining | n/a | 46.50 mm | n/a | 46.48 mm | n/a | n/a |
| Runway (months of cash) | n/a | 1891.7 | n/a | 1337.6 | n/a | n/a |
Institutional ownership, Q1 2021
48.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 6.09 mm |
| Total shares | 36.06 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Icahn Carl C Et Al | 36.06 mm | $6.09 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Jun 23 | Read Randolph C | Common Stock | Buy | Acquire P | No | No | 0.141 | 84,550 | 11.92 k | 200,000 |
| 14 Jun 23 | Read Randolph C | Common Stock | Buy | Acquire P | No | No | 0.1325 | 15,000 | 1.99 k | 115,450 |